Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Sorafenib for FLT3-ITD-positive AML

Andreas Burchert • 3 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Sorafenib
SORMAIN

Most patients with FLT3-ITD-positive acute myeloid leukemia (AML), who relapse after allogenic stem cell transplantation (ASCT) succumb to their disease. Here, Andreas Burchert, MD, of the University of Marburg, Marburg, Germany, discusses the SORMAIN trial (EUDRACT 2010-018539-16) assessing whether FLT3-ITD inhibition with sorafenib can prevent AML relapse, thus improving the outlook for patients in remission following ASCT. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA., Prof. Burchert reveals the practice-changing results showing sorafenib maintenance therapy after ASCT is feasible and significantly enhances OS in patients with FLT3-ITD-positive AML.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andreas Burchert

Optimizing transplantation outcomes for patients with AML
5:07
Optimizing transplantation outcomes for patients with AML
Andreas Burchert • 15 Oct 2021
Post-transplant maintenance strategies in AML
5:00
Post-transplant maintenance strategies in AML
Andreas Burchert • 15 Oct 2021
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
2:57
Sorafenib as SOC maintenance after allo-transplant in FLT3+ AML
Andreas Burchert • 15 Oct 2021
The future of AML therapy
1:44
The future of AML therapy
Andreas Burchert • 3 Jan 2019

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals